Serum adiponectin in chronic hepatitis C and B
Authors:
- 30 April 2007
- journal article
- Published by Wiley in Journal of Viral Hepatitis
- Vol. 14 (8) , 577-583
Abstract
Summary. Adiponectin possesses anti‐inflammatory, insulin‐sensitizing and anti‐atherosclerotic properties. The aim of this study was to assess the levels of serum adiponectin in patients with chronic viral hepatitis C and B and correlate them with parameters exploring insulin resistance and indices of chronic liver disease. Seventy‐two patients with chronic hepatitis C virus (HCV) infection and 73 patients with chronic hepatitis B virus (HBV) infection, matched for age and sex, were studied. All individuals were examined for serum concentrations of adiponectin, insulin, C‐peptide and homeostasis model assessment for insulin resistance (HOMA‐IR). Viral parameters and liver histology were also evaluated. Serum adiponectin levels were significantly higher in HCV compared with HBV‐infected patients. Correlation analysis in the whole group demonstrated that serum adiponectin was positively correlated with aspartate aminotransferase, alkaline phosphatase, globulins, high‐density lipoprotein cholesterol and staging score, while it was negatively correlated with body mass index, insulin, C‐peptide and HOMA‐IR. Logistic regression analysis identified type of infection (HCVvsHBV), alcohol consumption more than 25 g daily, serum total globulin and low C‐peptide as significant predictive variables associated with high adiponectin levels. Higher levels of serum adiponectin in HCV compared with HBV patients could have a role in the slower disease progression of chronic HCV infection. In addition, alcohol intake more than 25 g daily seems to be a significant predictor for hyperadiponectinaemia in patients with chronic viral hepatitis C or B. Finally, in this study, a clear positive association between adiponectin and hepatic necroinflammation or staging score was not found.Keywords
This publication has 31 references indexed in Scilit:
- Mechanisms of Disease: hepatic steatosis in type 2 diabetes—pathogenesis and clinical relevanceNature Clinical Practice Endocrinology & Metabolism, 2006
- Associations between plasma adiponectin concentrations and liver histology in patients with nonalcoholic fatty liver diseaseClinical Endocrinology, 2006
- Plasma adiponectin is decreased in nonalcoholic fatty liver diseaseEuropean Journal of Endocrinology, 2005
- Adiponectin, the missing link in insulin resistance and obesityClinical Nutrition, 2004
- Inverse association between serum adiponectin level and transaminase activities in Japanese male workersJournal of Hepatology, 2004
- Selective Suppression of Endothelial Cell Apoptosis by the High Molecular Weight Form of AdiponectinCirculation Research, 2004
- Decreased Plasma Adiponectin Concentrations Are Closely Related to Hepatic Fat Content and Hepatic Insulin Resistance in Pioglitazone-Treated Type 2 Diabetic PatientsThe Journal of Clinical Endocrinology & Metabolism, 2004
- Expression of adiponectin receptors in human macrophages and regulation by agonists of the nuclear receptors PPARα, PPARγ, and LXRBiochemical and Biophysical Research Communications, 2004
- The adipocyte-secreted protein Acrp30 enhances hepatic insulin actionNature Medicine, 2001
- Adiponectin, an Adipocyte-Derived Plasma Protein, Inhibits Endothelial NF-κB Signaling Through a cAMP-Dependent PathwayCirculation, 2000